Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: To investigate the risk of non-alcoholic fatty liver disease (NAFLD) for cardiovascular disease and all cause death in patients with type 2 diabetes mellitus (T2DM). Design: Nationwide population based study. Setting: Longitudinal cohort study in Korea. Participants: 7 796 763 participants in the National Health Screening Programme in 2009 were divided into three groups based on NAFLD status: no NAFLD (fatty liver index<30); grade 1 NAFLD (30≤fatty liver index<60); and grade 2 NAFLD (fatty liver index≥60). Median follow-up was 8.13 years. Main outcome measures: The primary outcome was incident cardiovascular disease (myocardial infarction, ischaemic stroke) or all cause death. Results: Of 7 796 763 participants, 6.49% (n=505 763) had T2DM. More patients with T2DM had grade 1 NAFLD (34.06%) and grade 2 NAFLD (26.73%) than those without T2DM (grade 1 NAFLD: 21.20%; grade 2 NAFLD: 10.02%). The incidence rate (per 1000 person years) of cardiovascular disease and all cause death increased in the order of no NAFLD, grade 1 NAFLD, and grade 2 NAFLD, and the incidence rates in patients with T2DM were higher than those in patients without T2DM. The five year absolute risk for cardiovascular disease and all cause death increased in the order of no NAFLD, grade 1 NAFLD, and grade 2 NAFLD in patients without and with T2DM (no NAFLD, without T2DM: 1.03, 95% confidence interval 1.02 to 1.04, and 1.25, 1.24 to 1.26, respectively; grade 1 NAFLD, without T2DM: 1.23, 1.22 to 1.25, and 1.50, 1.48 to 1.51, respectively; grade 2 NAFLD, without T2DM: 1.42, 1.40 to 1.45, and 2.09, 2.06 to 2.12, respectively; no NAFLD, with T2DM: 3.34, 3.27 to 3.41, and 3.68, 3.61 to 3.74, respectively; grade 1 NAFLD, with T2DM: 3.94, 3.87 to 4.02, and 4.25, 4.18 to 4.33, respectively; grade 2 NAFLD, with T2DM: 4.66, 4.54 to 4.78, and 5.91, 5.78 to 6.05, respectively). Patients with T2DM and without NAFLD had a higher five year absolute risk for cardiovascular disease and all cause death than those without T2DM and with grade 2 NAFLD. Risk differences for cardiovascular disease and all cause death between no NAFLD and grade 1 or grade 2 NAFLD were higher in patients with T2DM than in those without T2DM. Conclusions: NAFLD in patients with T2DM seems to be associated with a higher risk of cardiovascular disease and all cause death, even in patients with mild NAFLD. Risk differences for cardiovascular disease and all cause death between the no NAFLD group and the grade 1 or grade 2 NAFLD groups were higher in patients with T2DM than in those without T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
Younossi, Z., Anstee, Q. M., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J., & Bugianesi, E. (2018) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.109 · Cited by 5,249
The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study
Adams, L. A., Lymp, J. F., St. Sauver, J., Sanderson, S. O., Lindor, K. D., Feldstein, A., & Angulo, P. (2005) · Gastroenterology · doi:10.1053/j.gastro.2005.04.014 · Cited by 2,890
Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention
Huang, D. Q., El-Serag, H. B., & Loomba, R. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00381-6 · Cited by 1,855
Mantovani, A., Csermely, A., Petracca, G., Beatrice, G., Corey, K. E., Simon, T. G., Byrne, C. D., & Targher, G. (2021) · The Lancet Gastroenterology & Hepatology · doi:10.1016/s2468-1253(21)00308-3 · Cited by 674
Sattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555
10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Das, S. R., Hilliard, M. E., Isaacs, D., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s010 · Cited by 465
Alexander, M., Loomis, A. K., van der Lei, J., Duarte-Salles, T., Prieto-Alhambra, D., Ansell, D., Pasqua, A., Lapi, F., Rijnbeek, P., Mosseveld, M., et al. (2019) · BMJ · doi:10.1136/bmj.l5367 · Cited by 254 · cited 1×
“25 However, a systematic review and meta-analysis of 26 observational studies with 85 395 participants showed that patients with NAFLD had a higher risk of subclinical atherosclerosis than those in the non-NAFLD group (odds ratio 1.60, 95% confidence interval 1.45 to 1.78).”
InfluentialZhou, Y.-Y., Zhou, X.-D., Wu, S.-J., Hu, X.-Q., Tang, B., Poucke, S. V., Pan, X.-Y., Wu, W.-J., Gu, X.-M., Fu, S.-W., et al. (2018) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000001075 · Cited by 125
Vanjiappan, S., Hamide, A., Ananthakrishnan, R., Periyasamy, S. G., & Mehalingam, V. (2018) · Diabetes & Metabolic Syndrome: Clinical Research & Reviews · doi:10.1016/j.dsx.2018.01.001 · Cited by 45
Research works printed but not linked: 32
- 10.1002/hep.28431 · DOI · Paper page
- 10.4093/dmj.2022.0444 · DOI
- 10.1002/hep.26672 · DOI · Paper page
- 10.1002/oby.23438 · DOI
- 10.4093/dmj.2021.0327 · DOI
- 10.1016/j.metabol.2021.154770 · DOI · Paper page
- 10.1016/S2213-8587(22)00003-1 · DOI · Paper page
- 10.1007/s11892-021-01383-7 · DOI · Paper page
- 10.1016/j.jhep.2008.06.018 · DOI · Paper page
- 10.4093/dmj.2022.0106 · DOI · Paper page
- 10.4093/dmj.2020.0010 · DOI
- 10.2337/dc07-0349 · DOI · Paper page
- 10.2337/diabetes.54.12.3541 · DOI · Paper page
- 10.2337/dc17-1590 · DOI · Paper page
- 10.1186/1471-230X-6-33 · DOI · Paper page
- 10.4093/dmj.2019.0034 · DOI
- 10.3803/EnM.2022.102 · DOI
- 10.1002/hep4.1155 · DOI · Paper page
- 10.1016/j.jhep.2016.05.013 · DOI · Paper page
- 10.1016/S1665-2681(19)31850-2 · DOI
- 10.1530/EJE-14-0112 · DOI · Paper page
- 10.1097/MD.0000000000001682 · DOI · Paper page
- 10.1371/journal.pone.0107584 · DOI · Paper page
- 10.3390/diagnostics11122233 · DOI
- 10.1186/s12933-022-01483-y · DOI
- 10.1111/apt.16706 · DOI
- 10.1111/dom.14597 · DOI
- 10.1016/j.atherosclerosis.2019.01.029 · DOI
- 10.1007/s00125-019-05024-3 · DOI · Paper page
- 10.1016/S0735-1097(03)00088-3 · DOI · Paper page
- 10.1007/s00125-016-3952-1 · DOI · Paper page
- 10.1111/j.1478-3231.2011.02580.x · DOI
Cited by
Neeland, I. J., Lim, S., Tchernof, A., Gastaldelli, A., Rangaswami, J., Ndumele, C. E., Powell-Wiley, T. M., & Després, J.-P. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00563-5 · Cited by 463
“0123456789();: Primer a higher risk of CVD and all-cause death than those without MASLD (FLI <30) 213 .”
Cho, E. J., Chung, G. E., Yoo, J.-J., Cho, Y., Lee, K. N., Shin, D. W., Kim, Y. J., Yoon, J.-H., Han, K., & Yu, S. J. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02408-7 · Cited by 17
“The higher risk of AF in individuals with NAFLD and fibrosis is consistent with another study, indicating that NAFLD is associated with an enhanced risk of CVD [22].”
BackgroundResultSelf-citationCao, C., Liu, W., Guo, X., Weng, S., Chen, Y., Luo, Y., Wang, S., Zhu, B., Liu, Y., & Peng, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1460431 · Cited by 16
Chen, Y., Zhou, J., Tang, C., Zhu, P., Xu, Z., Song, X., Zhang, J., Cen, L., Zeng, H., Ke, Y., et al. (2025) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00824-5 · Cited by 4
“Beyond liver-related complications, MASLD is also a key risk factor for major adverse cardiovascular events, which constitute the leading cause of mortality among affected adults [6–9].”
Metadata
- Authors
- Kim, K.-S., Hong, S., Han, K., & Park, C.-Y.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2024-02-13
- Volume
- 384
- Pages
- e076388
- ISSN
- 1756-1833 (ISSN-L)
- OpenAlex
- W4391799523
- Cited by
- 173
- References
- 9
- FWCI
- 45.23
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. https://app.cochat.ai/papers/10.1136/bmj-2023-076388
- The paper
- Kim, K.-S., Hong, S., Han, K., & Park, C.-Y. (2024). Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. https://doi.org/10.1136/bmj-2023-076388
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.